
Background: Patient-reported health-related quality of life (PHRQoL) has emerged as an important outcome following percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS). While PCI improves survival and symptom burden, recovery may be influenced by ACS subtype and the presence of cardiometabolic comorbidities. This study evaluated longitudinal changes in PHRQoL following PCI and assessed the impact of diabetes mellitus (T2DM) and hypertension (HTN) on recovery trajectories. Methodology: This prospective observational cohort study included 119 patients with ACS (UA-n = 69; STEMI-n = 38; NSTEMI-n = 12) undergoing PCI at a tertiary care center. PHRQoL was assessed using the Duke Activity Status Index at 1 week, 1 month, and 3 months post-PCI. Patients were categorized according to comorbidity burden as no comorbidity, single comorbidity (T2DM or HTN), or dual comorbidity (T2DM and HTN). Multivariable linear regression analysis was performed to identify independent predictors of 3-month QoL. Results: Mean QoL improved significantly from 6.58 ± 2.71 at 1 week to 27.87 ± 7.34 at 1 month and 51.22 ± 10.11 at 3 months ( P < 0.001). STEMI patients demonstrated consistently lower QoL than UA and NSTEMI throughout follow-up. Increasing comorbidity burden was associated with progressively poorer recovery, with patients having dual comorbidity exhibiting the lowest 3-month QoL (34.5 ± 7.9). Recovery magnitude declined significantly with increasing comorbidity burden (partial η 2 = 0.32, P < 0.001). Multivariable regression identified comorbidity burden (β = −6.41, P < 0.001) and STEMI presentation (β = −7.82, P < 0.001) as independent predictors of lower 3-month QoL, whereas age and sex were not significant. Conclusions: PHRQoL improves substantially following PCI; however, recovery is significantly influenced by ACS subtype and cumulative cardiometabolic comorbidity burden. STEMI and the coexistence of diabetes and hypertension independently predict poorer functional recovery. Incorporating comorbidity burden into post-PCI risk stratification may facilitate targeted rehabilitation and improve patient-centered outcomes.
The Tirumala Temple attracts millions of pilgrims annually. This study aimed to evaluate the clinical spectrum and profile of Coronary Artery Disease (CAD) among pilgrims admitted with cardiac ailments to a tertiary care centre near Tirumala. This single-centre, retrospective observational study was conducted at a tertiary care hospital in Tirupati from June 2023 to June 2025. A total of 267 pilgrim patients admitted with cardiac complaints were included. Data on demographics, cardiovascular risk factors, diagnoses, and management strategies were analysed. The mean age was 56.7 years, with male predominance (74.5%). Diabetes (55.1%) and hypertension (52.8%) were common risk factors. Acute Coronary Syndrome was the predominant diagnosis, with STEMI (59.1%) most frequent. Single Vessel Disease was common, with LAD involvement in 79.2%. PTCA was performed in 54.1%, and in-hospital mortality was 2.9%. Pilgrims visiting Tirumala represent a high-risk cardiac group. Pre-travel cardiac evaluation and early hospitalization are essential to improve outcomes.
Cardiovascular infections represent a critical interface between infectious diseases and cardiology. Infective endocarditis, cardiac device-related infections, vascular graft infections, postoperative mediastinitis, and infective complications of rheumatic and congenital heart disease contribute substantially to morbidity, mortality, and healthcare costs. These conditions also drive antimicrobial resistance (AMR) through empirical broad-spectrum therapy, prolonged antimicrobial exposure, and inconsistent adherence to diagnostic and preventive strategies. The 42 practice points of the Society of Antimicrobial Stewardship PractIces (SASPI) in India provide an actionable framework for integrating antimicrobial stewardship (AMS) into cardiovascular medicine and surgery. This editorial highlights stewardship challenges, defines the role of cardiologists and cardiac surgeons in combating AMR, and translates SASPI recommendations into practical clinical strategies. Key priorities include culture-guided therapy, optimized perioperative prophylaxis, timely source control including device or graft removal, catheter-care bundles, outpatient parenteral antimicrobial therapy, and integration of cardiac teams into institutional AMS programs (A HEART AMSP model).
Background: Conventional blood pressure (BP) measurement devices using inflatable cuffs offer limited snapshots of BP profiles. Cuffless BP technologies enable continuous monitoring, potentially revolutionizing hypertension management by providing comprehensive daily data. Objective: To compare the accuracy of a commercially available cuffless BP monitor (V-CHEK device) against a mercury sphygmomanometer and pulse oximeter for measuring BP, heart rate, and oxygen saturation (SpO₂) in resting conditions. Methods: In this cross-sectional study at Sri Jayadeva Institute of Cardiovascular Sciences and Research, 250 patients underwent daytime BP, heart rate, and SpO₂ measurements using both the V-CHEK device and a mercury sphygmomanometer/pulse oximeter. Statistical analysis included Bland-Altman agreement assessment with 95% confidence intervals (CIs). Results: BP: No significant difference between devices; bias: −0.377 mmHg (95% CI: −0.758 to 0.004) Heart rate: Bias: −0.078 bpm (95% CI: −0.253 to 0.098). SpO₂: Marginal bias: 0.173% (95% CI: −0.23 to −0.103). All parameters showed strong agreement, with SpO₂ demonstrating slightly lower concordance. Conclusion: The V-CHEK cuffless device provides BP, heart rate, and SpO₂ measurements comparable to traditional sphygmomanometry in resting conditions, supporting its potential for clinical and ambulatory use.